Three insights:
1. ARMI includes over 100 organizations from industry, government, academia and the nonprofit sector to develop manufacturing processes and technologies for cells, tissue and organs.
2. ARMI’s goal is to integrate the arsenal of industry practices and competency in tissue biofabrication technology to expand the position of the U.S. in relation to its competition.
3. AlloSource will help accelerate regenerative tissue research and develop manufacturing systems in biomaterial and cell processing for the Department of Defense.
“Over the past 25 years, we have advanced our processes and tissue products to help surgeons heal millions of patients needing orthopedic, spine, burn and wound procedures … we will continue to honor our mission through the development of regenerative therapies,” said Thomas Cycyota, president and CEO of AlloSource.
More articles on biologics:
Ortho RTi unveils new CEO — 4 quick insights
Minnesota seeks to expand stem cell research through state initiative — 4 insights
Stem cell controversies — Where we are in 2019
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
